Azathioprine, cyclophosphamide and chlorambucil (Q37799087)

23 August 2017

1 reference

title

Azathioprine, cyclophosphamide and chlorambucil (English)

1 reference

23 August 2017

0 references

Luqmani RA

1 reference

23 August 2017

Palmer RG

series ordinal

1 reference

23 August 2017

Bacon PA

series ordinal

1 reference

23 August 2017

publication date

1 December 1990

1 reference

Bailliere's clinical rheumatology

23 August 2017

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

595-619

1 reference

Long-lasting remission of Behcet's disease after chlorambucil therapy

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Malignancy following treatment of rheumatoid arthritis with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Infectious complications of cyclophosphamide treatment for vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Prednisone and azathioprine for polymyositis: long-term followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Chlorambucil treatment in minimal lesion nephrotic syndrome: a reappraisal of its gonadal toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Polymorphonuclear leukocytes in immunologic reactions. The destruction of vascular basement membrane in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

NIH conference. Systemic lupus erythematosus: evolving concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Long-term azathioprine in rheumatoid arthritis: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Rheumatoid disease with joint and pulmonary manifestations.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Sterility and testicular atrophy related to cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Long-term cyclophosphamide therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

A combined clinical and immunological assessment of four cyclophosphamide regimes in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Further Experience with Azathioprine in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Chlorambucil allergy--a series of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Intermittent cyclophosphamide in refractory rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in rheumatoid arthritis: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Treatment of Wegener's granulomatosis of lung

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

The relationship of therapy with cortisone to the incidence of vascular lesions in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Cancer in patients treated with immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Treatment of intractable rheumatoid arthritis with total lymphoid irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Immunosuppressive and corticosteroid therapy of polyarteritis nodosa

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

The effect of azathioprine on gammaglobulin synthesis in man

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Double-blind study of cyclophosphamide in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

The metabolism of chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Treatment of Behçet's disease with chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Multiple late complications of therapy with cyclophosphamide, including ovarian destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Clinical infections, antibiotics and immunosuppression: a puzzling relationship

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Herpes zoster in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Cyclophosphamide Therapy in Wegener's Granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Malignancies induced by chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Chlorambucil induced chromosome damage in juvenile chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Thioguanine-resistant mutations induced by cytotoxic drugs in lymphocytes of patients with connective tissue diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Use of T cell cloning to detect in vivo mutations induced by cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

The oncogenicity of chlorambucil in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Drug 'administration' via breast milk

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

A chromosome study of patients with uveitis treated with chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

1 reference

7 January 2021

Genetic activity of chemicals in yeast: DNA alterations and mutations induced by alkylating anti-cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Immunosuppressive and Cytotoxic Chemotherapy: Long-Term Complications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Exacerbation of Systemic Lupus Erythematosus after Withdrawal of Azathioprine Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

The treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Stage-adapted treatment of Wegener's granulomatosis. First results of a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Cyclophosphamide-induced bladder toxicity in wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in the treatment of systemic lupus erythematosus. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Chlorambucil in Behçet's disease. A reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

The Effect of Cyclophospkamide on the Immune Response

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in rheumatoid arthritis. A double-blind, cross over study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Combined suppressive drug treatment in severe refractory rheumatoid disease: an analysis of the relative effects of parenteral methylprednisolone, cyclophosphamide, and sodium aurothiomalate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Cryoimmunoglobulinemia in rheumatoid arthritis. Significance in serum of patients with rheumatoid vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

A controlled trial of azathioprine in Behçet's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

Irreversible Liver Damage After Azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980009-3

7 January 2021

10.1016/S0950-3579(05)80009-3

Identifiers

DOI

1 reference

23 August 2017

1 reference